Virtual Conference
Maritza Torres Valdez

Maritza Torres Valdez

University of Zulia, Ecuador

Title: Systematic review: Reduction of cardiovascular events of lomitapide versus statins in patients diagnosed with familial hypercholesterolemia, randomized clinical outcomes study


Familial Hypercholesterolemia (FH) is an autosomal dominant genetic disorder that causes elevations in Low-Density Lipoprotein (LDL) cholesterol. These high LDL levels lead to the rapid development of early atherosclerosis, resulting in the premature development of Atherosclerotic Cardiovascular Disease (ASCVD). Patients with FH require aggressive treatment to reduce LDL cholesterol levels and the risk of ASCVD. Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as a drug for the treatment of Familial Hypercholesterolemia (FH). It acts by binding directly and selectively to MTP, decreases the assembly and secretion of apo-B-containing lipoproteins. Statins are the group of drugs of choice in patients with FH. They act by inhibiting the enzyme hydroxymethylglutaryl CoA reductase, which controls cholesterol production in the liver. However, people at high risk of CVD are intolerant to statin therapy or do not reach their treatment goals. 

The objective of this systematic review is to determine how Lomitapide influences the reduction of cardiovascular events in patients diagnosed with familial hypercholesterolemia. The approach in the pharmacological treatment of familial hypercholesterolemia is based on the reduction of LDL levels, this is achieved with the early introduction of the drug of choice is statins with respect to the age of onset in the pediatric population. This review compares these two drugs, evaluating the reduction of LDL cholesterol levels, the reduction of the risk of cardiovascular events and therefore also mortality. This review will try to compare the efficacy of Lomitapide in the reduction of cardiovascular events in this type of pathology, comparing its results with those obtained with statins, which is the drug of choice in this pathology.


Maritza Torres Valdez, has a Ph.D. in Human Metabolism from the University of Zulia, a Master in Endocrinology from the University of Alcala and a specialist in family medicine from the University of Azuay. She is currently a treating physician for the Ministry of Public Health of Ecuador and is part of research teams within the country with 55 published articles and 232 citations.